三阴性乳腺癌与BRCA1基因突变风险相关性的Meta分析  

Association between the triple-negative breast cancer and the risk of BRCA1 mutation： a Meta-analysis

作　　者：张莉[1] 龙行华[1] 

机构地区：[1]武汉大学中南医院检验科,430071

出　　处：《国际肿瘤学杂志》2015年第1期32-36,共5页Journal of International Oncology

基　　金：国家自然科学基金（30873044、81272372）;教育部留学回国人员科研启动基金（教外司留[2011]1139号）

摘　　要：目的 对三阴性乳腺癌患者发生BRCA1基因突变风险进行系统综合评价.方法 从PubMed、中国期刊全文数据库、万方、维普、中国生物医学文献数据库中检索相关文献,用比值比（OR）评价三阴性乳腺癌患者发生BRCA1基因突变的风险,用Rev-Man 5.2软件进行Meta分析.结果 共纳入23篇文献,其中三阴性乳腺癌患者1 104例,非三阴性乳腺癌患者4 245例.合并OR及95％ CI为7.67（6.24 ～ 9.42）,差异有统计学意义（Z=19.38,P＜0.000 01）.在有关人种的亚组分析中,亚洲人合并OR及95％ CI为6.67（4.98 ～8.95）,高加索人合并OR及95％ CI为8.83（6.61～11.80）,差异有统计学意义（Z=14.74,P＜0.000 01）.结论 BRCA1基因在三阴性乳腺癌患者中的突变风险是非三阴性乳腺癌患者的7.67倍.需要大样本的随机对照试验进一步证实,从而使得BRCA1基因突变检测可以常规应用于临床三阴性乳癌患者中.Objective To systematically evaluate the risk of BRCA1 mutation in patients with triplenegative breast cancer （TNBC）.Methods Articles about the association between the TNBC and BRCA1 mutation were retrieved from database,such as PubMed,CNKI,Wanfang,VIP and CBM databases.The odds ratio （OR） was used to evaluate the risk of BRCA1 mutation in TNBC compared with non-TNBC.Rev Man 5.2 software was applied to perform the Meta-analysis.Results A total of 23 articles were eligible for the Meta-analysis,including 1 104 patients with TNBC and 4 245 patients with non-TNBC.The pooled OR was 7.67 and 95％ CI（6.24,9.42）,and the difference was statistically significant （Z =19.38,P ＜ 0.000 01）.In the subgroup analysis about the race,the pooled OR for Asian was 6.67 and 95％ CI （4.98,8.95）.The pooled OR for Caucasian was 8.83 and 95％ CI （6.61,11.80）.There was statistically significant difference in the pooled OR between the Asian and the Caucasian （Z =14.74,P ＜ 0.000 01）.Conclusion The patients with TNBC are 7.67 times more likely to have BRCA1 mutation compared with non-TNBC phenotype.Largesample randomized controlled trials are warranted to demonstrate the detection of BRCA1 mutation can be a conven-tional application in clinical for the patients with TNBC.

关 键 词：乳腺肿瘤 基因 BRCA1 META分析 

分 类 号：R737.9[医药卫生—肿瘤] R440[医药卫生—临床医学]